TXG241220P17500
- 3.35
- +0.55+19.64%
10x Genomics Newsroom
10x Genomics (NASDAQ:TXG Investor Three-year Losses Grow to 89% as the Stock Sheds US$73m This Past Week
Trump's Unusual Pick for NIH Director May Be a Win for These Stocks -- Barrons.com
10x Banking and Alloy Partner to Bring Cloud-native Risk Decisioning to Financial Services
If RFK Jr. Cuts Science Funding, These Instrument Makers May Suffer -- Barrons.com
10x Genomics, Inc. (TXG): Among the Best Genomics Stocks to Buy Right Now
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
Top Institutions Continue to Hold Strong Tech Positions in Q3 13F Filings
Ray Dalio's Bridgewater Cuts Stake In Microsoft Stock By 20% – Is Big Tech Losing Its Shine?
ARKK's Holdings Ranked by SA Quant Grades
10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts
Barclays Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $19
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
Morgan Stanley Maintains 10x Genomics(TXG.US) With Buy Rating, Maintains Target Price $30
A Quick Look at Today's Ratings for 10x Genomics(TXG.US), With a Forecast Between $14 to $30
TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative
These Analysts Boost Their Forecasts On 10x Genomics After Q3 Results
10x Genomics Is Maintained at Neutral by JP Morgan
UBS Maintains Neutral on 10x Genomics, Lowers Price Target to $20
10x Genomics Analyst Ratings